Subclinical thyroid disorders: significance and clinical impact

被引：35

作者：

Razvi, Salman ^{[1
,2
]}

Weaver, Jolanta U. ^{[1
,3
]}

Pearce, Simon H. S. ^{[2
,4
]}

机构：

[1] Gateshead Hlth NHS Fdn Trust, Dept Endocrinol, Gateshead, England

[2] Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne, Tyne & Wear, England

[3] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England

[4] Royal Victoria Infirm, Endocrine Unit, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England

来源：

JOURNAL OF CLINICAL PATHOLOGY | 2010年 / 63卷 / 05期

基金：

英国医学研究理事会;

关键词：

ISCHEMIC-HEART-DISEASE; L-THYROXINE TREATMENT; THYROTROPIN REFERENCE RANGE; PLACEBO-CONTROLLED TRIAL; ALL-CAUSE MORTALITY; 20-YEAR FOLLOW-UP; SERUM THYROTROPIN; DOUBLE-BLIND; RISK-FACTOR; STIMULATING HORMONE;

D O I：

10.1136/jcp.2008.057414

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Subclinical thyroid diseases are defined by abnormal serum thyroid stimulating hormone (TSH) levels associated with normal thyroid hormone concentrations. The diagnosis of these conditions depends on defining the 'normal' euthyroid TSH range; in this review, arguments for and against lowering the upper limit of TSH are summarised. Although, subclinical hypothyroidism and subclinical hyperthyroidism are frequently encountered, their long-term consequences are debated due to conflicting results from many observational studies. The causes, effects and outcomes of treatment of both subclinical diseases are described, and the direction of future research in these conditions is outlined.

引用

页码：379 / 386

页数：8

共 93 条

[1] Diagnosis and treatment of primary hypothyroidism [J].